R
Rachel Hodge
Researcher at GlaxoSmithKline
Publications - 9
Citations - 1926
Rachel Hodge is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Pazopanib & Cancer. The author has an hindex of 8, co-authored 9 publications receiving 1622 citations.
Papers
More filters
Journal ArticleDOI
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Dong Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohammed R. Dewji,Corneel Coens,George D. Demetri,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Peter Hohenberger +22 more
TL;DR: This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Journal ArticleDOI
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
Bernd Kasper,Stefan Sleijfer,Saskia Litière,Sandrine Marreaud,Jaap Verweij,Rachel Hodge,Sebastian Bauer,J.M. Kerst,W.T.A. van der Graaf +8 more
TL;DR: A retrospective analysis on pooled data from two EORTC trials on pazopanib in STS confirmed the importance of known prognostic factors in metastatic STS patients treated with systemic treatment, such as performance status and tumor grading, and additionally hemoglobin at baseline as new prognostic factor.
Journal ArticleDOI
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Corneel Coens,Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Ian Judson,Roberta Sanfilippo,Stephanie Manson,Rachel Hodge,Sandrine Marreaud,Judith B. Prins,Iwona Lugowska,Saskia Litière,Andrew Bottomley +12 more
TL;DR: In the PALETTE trial of pazopanib 800 mg versus placebo as second-line or later treatment for patients with advanced soft tissue sarcoma (N = 369) as discussed by the authors, progression-free survival was significantly improved in the PZPANib arm (median, 4.6 vs 1.6 months; hazard ratio, 0.31; P <.001), and toxicity of pZPanib consisted mainly of fatigue, diarrhea, nausea, weight loss, and hypertension.
Journal ArticleDOI
PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072).
W.T.A. van der Graaf,J.-Y. Blay,Shanta Chawla,Dong Wook Kim,B. Bui Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,A. Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohamedraza Dewji,A. P. Dei Tos,Peter Hohenberger +19 more
TL;DR: Pazopanib is an active drug in anthracycline pretreated metastatic STS pts with an increase in median PFS of 13 weeks with a statistically non-significant improvement in overall survival.
Journal Article
Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies.
Diane Boswell,Keld Ostergaard,Richard Philipson,Rachel Hodge,David Blum,Judith Brown,Steve Quessy +6 more
TL;DR: Overall, clinically meaningful efficacy in pain related to OA of the knee was not demonstrated for GW406381 despite its peripheral and central sites of action.